GLP-3

GLP-3 (LY3437943) is an investigational synthetic triagonist peptide developed to simultaneously target the GLP-1, GIP, and glucagon (GCG) receptor pathways. Through combined receptor activation, GLP-3 has been extensively studied in laboratory and clinical research settings involving metabolic regulation, body composition, energy expenditure, glucose homeostasis, and hepatic function. This multi-pathway mechanism differentiates GLP-3 from earlier single-pathway incretin compounds by integrating appetite modulation, insulin signaling, delayed gastric emptying, and enhanced metabolic expenditure into a unified investigational profile. Research suggests GLP-3 may influence several interconnected metabolic systems simultaneously. Activation of GLP-1 and GIP receptors has been associated with improved insulin sensitivity, glucose regulation, and appetite signaling, while glucagon receptor activation has been investigated for its role in promoting lipolysis, fatty acid oxidation, and increased basal energy expenditure. Through this combined receptor activity, GLP-3 has demonstrated significant investigational potential in studies involving obesity, insulin resistance, metabolic syndrome, and body-fat regulation. Clinical investigations have also explored GLP-3 in models involving hepatic steatosis and cardiometabolic health. Research observations have reported substantial reductions in liver fat accumulation, improvements in fasting glucose markers, insulin response pathways, blood pressure, lipid metabolism, and body weight regulation over extended study periods. These findings have positioned GLP-3 among the most extensively studied next-generation metabolic triagonist compounds currently undergoing clinical investigation. Manufactured to strict research-grade standards, each batch undergoes independent analytical verification through ISO-accredited laboratories for identity, purity, sterility, and consistency.